{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"169a9572b236b2cca4bd362065a904bddf42df919505e9e3cd1bfd3face0d6d8","attributes":{"feedName":"fda","feedSource":"fda","title":"Glenmark Pharmaceuticals Inc., USA Voluntarily Recalls All Unexpired Lots of its Ranitidine Tablets and Ceases Distribution, Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity","description":"Glenmark Pharmaceutical Inc., USA (“Glenmark”) today announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300 mg, to the consumer level.","link":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-its-ranitidine-tablets-and","publicationDate":"2019-12-18T01:16:33.000Z","state":"sent","affected":[],"allergens":[],"audience":["consumers","professionals"],"categories":["drugs"],"contaminants":["other"],"distribution":["AK","AL","AR","AZ","CA","CO","CT","DC","DE","FL","GA","HI","IA","ID","IL","IN","KS","KY","LA","MA","MD","ME","MI","MN","MO","MS","MT","NC","ND","NE","NH","NJ","NM","NV","NY","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VA","VT","WA","WI","WV","WY"],"risk":"possible","token":"5df98b55208e6100010401e9"}}}